17 result(s) for 'RNAscope'
1 - 10 of 17 results for 'RNAscope'
Sort by
Show
This detection system is for in vitro diagnostic use.The BOND RNAscope® Brown Detection enables the user to perform chromogenic in situ hybridization (CISH) with Advanced Cell Diagnostics (ACD) proprietary RNA ISH probes. Performance claims for compatible probes have not been established. Probes used in conjunction with BOND RNAscope® Brown Detection should be validated by the user in accordance with local laws and regulations. The BOND RNAscope®...
Incorporation and Automation of RNAscope Technology into your COVID-19 Viral Pathogenesis Research. Research Use Only, Not for Clinical Diagnostic Procedure
For Research Use Only. Not For Diagnostic Use. Incorporation of the highly sensitive and specific RNAscope technology into your COVID-19 Viral Pathogenesis Research Jyoti Sheldon Applications Research Use Only, Not for Clinical Diagnostic Procedure
Agenda RNAscope technology overview COVID-19 Offerings COVID-19 Publications Research Use Only, Not for Clinical Diagnostic Procedure
RNAscope®In Situ Hybridization (ISH) Technology A hybridization-based signal amplification system with a unique probe design - Simultaneous signal amplification and background suppression Amplification Target-specific binding A specific and sensit...
Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform
Leica Biosystems, in partnership with Bio-Techne Corporation, announces the automation of RNAscope™ COVID-19 probes’ on BOND RX*, its staining platform, for research use only. Researchers now have the capability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.
“We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment ...
This white paper highlights the value of an integrated ISP-in situ hybridization (ISH) workflow for co-detection of protein and RNA targets on a single FFPE tissue section.
CAMBRIDGE, MASS., JANUARY 31, 2022.
Companion diagnostic supports patient identification and enrollment into clinical trials of Leap Therapeutics‘ DKK1 inhibitor, DKN-01
Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company, to develop a companion diagnostic to detect Dickkopfrelated protein 1 (DKK1). The assay will be used to support the clinical development of Leap Therapeutics’ anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.
DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth. Overexpression of DKK1 is associated with poor survival in cancer patients. Leap Therapeutics is currently ...
Following a PhD and postdoc in the field of developmental neurobiology, I joined the experimental histopathology team at the Crick in 2017. Within the science technology platform, I primarily lead on the development and application of advanced staining techniques including immunohistochemistry, immunofluorescence, multiplexed staining, and RNAscope.
Jyoti Phatak-Sheldon holds a Master’s degree in Molecular and Cell Biology along with a Bachelors in Dental Surgery. She has previously worked in the field of genomics and precision diagnostics as a product specialist for qPCR-based liquid biopsy tests. Jyoti currently works at Advanced Cell Diagnostics as an associate scientist in the applications team to execute projects and collaborations that demonstrate novel applications of RNAscope and BaseScope™ assays.